We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Plaqenil Role in Prevention of Age Related Macular Degeneration

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01541449
Recruitment Status : Unknown
Verified January 2012 by Ziv Hospital.
Recruitment status was:  Recruiting
First Posted : March 1, 2012
Last Update Posted : March 1, 2012
Information provided by (Responsible Party):
Ziv Hospital

Brief Summary:
The investigators think that there is a connection between the use of plaquenil and the prevention of Age related macular degeneration (AMD). The investigators believe that the use of plaquenil makes bruch's membrane thicker, thereby preventing Chroidal Neovascularization (CNV) growth.

Condition or disease
Age Related Macular Degeneration

Detailed Description:
the study is done by comparing to groups RA patients who take plaquenil Vs. group of patients who do not take plaquenil. after measuring the retina thickness we compare the avg. thickness of both groups.

Study Type : Observational
Estimated Enrollment : 30 participants
Observational Model: Case Control
Time Perspective: Retrospective
Official Title: Observational Study Between People That Use Plaquenil and Those Who do Not in Prevention of AMD.
Study Start Date : January 2012
Estimated Study Completion Date : April 2012

Resource links provided by the National Library of Medicine

U.S. FDA Resources

RA patients treated with plaquenil
Patients who do not use plaquenil

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Ziv Medical center retina clinic population

Inclusion Criteria:

  • all people who suffer from rheumatoid arthritis (RA) and use plaquenil

Exclusion Criteria:

  • patients who did not complete follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01541449

Contact: Joseph Pikkel, M.D 0508434206 pikel.y@ziv.health.gov.il

Ziv Medical Center Recruiting
Safed, Israel, 13100
Contact: Otzem Chassid, M.D    0506266059    otzem@yahoo.com   
Sponsors and Collaborators
Ziv Hospital
Principal Investigator: Joseph pikkel, M.D Ziv Medical Center

Responsible Party: Ziv Hospital
ClinicalTrials.gov Identifier: NCT01541449     History of Changes
Other Study ID Numbers: ZIV-0061-11
First Posted: March 1, 2012    Key Record Dates
Last Update Posted: March 1, 2012
Last Verified: January 2012

Keywords provided by Ziv Hospital:

Additional relevant MeSH terms:
Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents